Simulations Plus, Inc. - SLP STOCK NEWS

Simulations Plus, Inc. (NASDAQ: SLP) announced a funded contract with the FDA to advance in vitro and physiology-based pharmacokinetics (PBPK) models for inhaled drug development. This collaboration aims to enhance the Pulmonary Compartmental Absorption and Transit (PCAT™) model, using data from healthy and patient samples to validate and propose alternatives for bioequivalence studies. The project is a continuation of Simulations Plus's commitment to improving drug development processes while minimizing the need for human and animal studies.

Simulations Plus, a leader in pharmaceutical modeling software, reported a 16% revenue increase year-over-year to $53.9 million for FY 2022. Diluted earnings per share rose 28% to $0.60. Q4 revenue surged 19% to $11.7 million, driven by a 30% increase in services revenue, while gross margin improved to 77%. For FY 2023, the company projects a revenue between $59.3 million and $62.0 million, signaling expected growth of 10% to 15%.

Simulations Plus (NASDAQ: SLP) has declared a quarterly cash dividend of $0.06 per share, scheduled for payment on November 7, 2022. Shareholders of record as of October 31, 2022 will receive this dividend. The decision for future dividends will be made quarterly by the Board based on earnings, financial situation, capital needs, and other considerations.

Simulations Plus has been a leader in the biosimulation market for over 25 years, providing essential software and consulting services to support drug discovery and development.

Simulations Plus (NASDAQ: SLP) has announced the launch of version 9.8.3 of its GastroPlus software, enhancing its physiologically based biopharmaceutics modeling capabilities. Key updates include improved reporting templates for Monolix, new validated disease populations for NAFL and NASH, a swine PBPK model for veterinary research, and flexible dosing regimen handling. The company aims to strengthen software interoperability and provide researchers with advanced simulation tools. This release reflects the company's ongoing commitment to integrating machine learning and quantitative systems pharmacology in drug development.

Simulations Plus (NASDAQ: SLP) is set to announce its fourth quarter and full year financial results for fiscal year 2022, ending August 31, 2022, following market closure on October 26, 2022. The company will host a conference call at 5:00 PM ET that day, inviting all interested parties to participate. The call can be accessed via registration or by calling in. Simulations Plus has been a key player in the biosimulation market for over 25 years, providing essential software and consulting services for drug discovery and regulatory submissions.

Simulations Plus, Inc. (Nasdaq: SLP) has announced that CEO Shawn O’Connor will present at the Sidoti Fall Small Cap Investor Conference on September 22, 2022, at 10:45 a.m. ET. The conference will be held virtually on September 21-22, 2022, where O’Connor will engage with investors throughout the day. The presentation will be webcast live and available for replay on the Simulations Plus investor page. For additional details about the conference, visit the conference website or contact Brian Siegel at Hayden IR.

Simulations Plus, a leader in biosimulation software, will present at Baird’s 2022 Global Healthcare Conference on September 14, 2022, at 2:00 p.m. ET. CEO Shawn O’Connor will discuss the company's advancements in modeling and simulation for pharmaceutical safety and efficacy. The session will be webcast live and available for replay on the Simulations Plus website. Established for over 25 years, Simulations Plus provides innovative solutions to major pharmaceutical and regulatory agencies worldwide.

Simulations Plus has launched ILDsym™ version 1A, a quantitative systems pharmacology modeling software aimed at enhancing therapy development for Interstitial Lung Disease (ILD)